PAQR8 and neoplasm: The competitive advantage exhibited by Paqr8-OE, and competitive disadvantage exhibited by Paqr8-KO, tumor cells following Her2 downregulation could potentially result from Paqr8-mediated differences in cell survival, proliferation, or both.